Analysts Set Fractyl Health, Inc. (NASDAQ:GUTS) PT at $5.40

Fractyl Health, Inc. (NASDAQ:GUTS) has been given an average recommendation of “Hold” by the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $5.40.

A number of equities analysts have weighed in on the stock. Morgan Stanley cut shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $8.00 to $2.00 in a research report on Thursday, January 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research note on Tuesday, December 2nd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Friday, December 19th.

Fractyl Health Trading Down 1.2%

NASDAQ GUTS opened at $0.50 on Monday. The stock has a market cap of $68.38 million, a P/E ratio of -0.22 and a beta of 1.51. The company’s fifty day simple moving average is $1.27 and its 200-day simple moving average is $1.34. Fractyl Health has a 52 week low of $0.38 and a 52 week high of $3.03.

Institutional Investors Weigh In On Fractyl Health

Institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC bought a new stake in Fractyl Health in the third quarter valued at about $19,298,000. 683 Capital Management LLC grew its position in shares of Fractyl Health by 30.1% in the 4th quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock worth $13,305,000 after acquiring an additional 1,397,620 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Fractyl Health by 234.9% in the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock valued at $13,039,000 after acquiring an additional 4,156,969 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Fractyl Health during the 3rd quarter valued at approximately $8,981,000. Finally, Woodline Partners LP lifted its stake in Fractyl Health by 821.1% during the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock worth $8,755,000 after purchasing an additional 4,908,693 shares during the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.